# EDGAR Filing Document

**Accession Number:** 0001133818
**File Stem:** 0001104659-25-077665
**Filing Date:** 2025-8
**Character Count:** 7401
**Document Hash:** 7994264f5ab6e6f8dc09840d63c4a1ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-077665.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001104659-25-077665

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250813

**ITEM INFORMATION**: Changes in Registrant's Certifying Accountant

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-PATH HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001133818
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870652870
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36333
- **FILM NUMBER:** 251213114

**BUSINESS ADDRESS:**
- **STREET 1:** 4710 BELLAIRE BOULEVARD
- **STREET 2:** SUITE 210
- **CITY:** BELLAIRE
- **STATE:** TX
- **ZIP:** 77401
- **BUSINESS PHONE:** (832) 742-1357

**MAIL ADDRESS:**
- **STREET 1:** 4710 BELLAIRE BOULEVARD
- **STREET 2:** SUITE 210
- **CITY:** BELLAIRE
- **STATE:** TX
- **ZIP:** 77401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIO-PATH HOLDINGS INC
- **DATE OF NAME CHANGE:** 20080221

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OGDEN GOLF CO CORP
- **DATE OF NAME CHANGE:** 20010205

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT**

**TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): August 13, 2025

**BIO-PATH HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36333** | **87-0652870** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **4710 Bellaire Boulevard** **, Suite 210, Bellaire, Texas** | **77401** |
| (Address of principal executive offices) | (Zip Code) |

---

(832) 742-1357

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | BPTH | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 4.01 Changes in Registrant's Certifying Accountant.**

(a) <u>Dismissal of Previous Independent Registered Public Accounting Firm</u>.

On August 13, 2025, the Board of Directors of Bio-Path Holdings, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm, and notified EY of the dismissal on the same date with an effective date of August 13, 2025.

EY's reports on the Company's financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except for the explanatory paragraph relating to the Company's ability to continue as a going concern contained in EY's reports on the Company's financial statements for each of the fiscal years ended December 31, 2024 and 2023.

During the Company's two most recent fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through August 13, 2025, there were (i) no "disagreements" within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused it to make reference to the subject matter of the disagreements in connection with its reports on the financial statements of the Company for such years, and (ii) no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K.

The Company has provided EY with a copy of the foregoing disclosures and has requested that EY furnish the Company with a letter addressed to the SEC stating whether it agrees with such disclosures and, if not, stating the respects in which it does not agree. EY's letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.

The Company is actively seeking a new independent registered public accounting firm and intends to engage a firm as soon as practicable. However, there can be no assurance as to the timing of such engagement. Once a new firm is engaged, the Company will file a Current Report on Form 8-K disclosing such engagement. The Company expects to authorize EY to respond fully to the inquiries of the successor independent accounting firm once engaged, including those related to prior years' audits.

**Item 9.01 Financial Statements and Exhibits.**

(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| Exhibit |  |
| Number | Description |
| [16.1\*](tm2523449d1_ex16-1.htm) | [Letter of Ernst & Young LLP, dated August 13, 2025.](tm2523449d1_ex16-1.htm) |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BIO-PATH HOLDINGS, INC.** | **BIO-PATH HOLDINGS, INC.** |
| Dated: August 13, 2025 | By: | /s/ Doug P. Morris |
|  |  | Doug P. Morris |
|  |  | Chairman of the Board of Directors |

---

## Exhibit 16.1

**Exhibit 16.1**

August 13, 2025

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Ladies and Gentlemen:

We have read Item 4.01 of Form 8-K dated August 13, 2025 of Bio-Path Holdings, Inc., and are in agreement with the statements contained in the first through fourth paragraphs therein. We have no basis to agree or disagree with other statements of the registrant contained therein.

/s/ Ernst & Young LLP